– Blue Shield of California has over 3 million covered members
in CA –
SAN
FRANCISCO, March 6, 2023 /PRNewswire/ -- Invitae
(NYSE: NVTA), a leading medical genetics company, today announced
that its Personalized Cancer Monitoring (PCM™) assay, which helps
detect minimal residual disease (MRD) in patients, has obtained its
first commercial coverage in all solid tumors by Blue Shield of
California. The policy, effective
as of March 1, 2023, considers the
test medically necessary for patients with stage I-IV cancer after
surgical intervention for adjuvant or targeted therapy and/or
monitoring for relapse or progression.
Invitae's PCM uses a novel set of personalized assays based on a
patient's tumor to detect circulating tumor DNA (ctDNA) in blood,
assisting with risk stratification, assessing response to treatment
and detecting cancer recurrence.
"We are very pleased with this coverage decision because it
recognizes the utility of PCM in detecting MRD, thereby improving
the clinical care of cancer patients," said Robert Nussbaum, M.D., chief medical officer at
Invitae. "We are continuing to generate additional clinical
evidence as well as securing other reimbursement pathways. Overall,
we are encouraged to see increasing access to MRD testing and view
the coverage decision as a great step forward for patients."
For more information, visit invitae.com.
About Invitae
Invitae (NYSE: NVTA) is a leading
medical genetics company trusted by millions of patients and their
providers to deliver timely genetic information using digital
technology. We aim to provide accurate and actionable answers to
strengthen medical decision-making for individuals and their
families. Invitae's genetics experts apply a rigorous approach to
data and research, serving as the foundation of their mission to
bring comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people.
To learn more, visit invitae.com and follow for
updates on Twitter, Instagram,
Facebook and LinkedIn @Invitae.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the company's beliefs regarding the coverage decision,
the utility of PCM and its benefits for patients; and the company's
plans regarding generating additional clinical evidence and
securing other reimbursement. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the company's
history of losses; the company's ability to compete; the company's
need to scale its infrastructure in advance of demand for its tests
and to increase demand for its tests; the company's ability to use
rapidly changing genetic data to interpret test results accurately
and consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Annual Report on Form 10-K for the year
ended December 31, 2022. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Invitae PR contact:
Renee Kelley
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitaes-pcm-assay-for-minimal-residual-disease-receives-its-first-commercial-coverage-301762882.html
SOURCE Invitae Corporation